Grading risk of microvascular invasion impacts survival in hepatocellular carcinoma patients undergoing adjuvant transarterial chemoembolization: A multicenter study.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: microvascular invasion (MVI) following liver resection (LR), and explore whether grading risk of MVI can impact the survival of HCC patients undergoing PA-TACE
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] PA-TACE should be performed selectively in HCC patients with high-risk MVI after curative liver resection. Nonetheless, for HCC patients with low-risk MVI, PA-TACE is not recommended.
[PURPOSE] To investigate the influence of postoperative adjuvant transarterial chemoembolization (PA-TACE) on the prognosis of hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI)
- p-value P = 0.032
- p-value P = 0.023
APA
Lu JP, Feng JK, et al. (2025). Grading risk of microvascular invasion impacts survival in hepatocellular carcinoma patients undergoing adjuvant transarterial chemoembolization: A multicenter study.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 51(8), 110102. https://doi.org/10.1016/j.ejso.2025.110102
MLA
Lu JP, et al.. "Grading risk of microvascular invasion impacts survival in hepatocellular carcinoma patients undergoing adjuvant transarterial chemoembolization: A multicenter study.." European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 51, no. 8, 2025, pp. 110102.
PMID
40300381 ↗
Abstract 한글 요약
[PURPOSE] To investigate the influence of postoperative adjuvant transarterial chemoembolization (PA-TACE) on the prognosis of hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI) following liver resection (LR), and explore whether grading risk of MVI can impact the survival of HCC patients undergoing PA-TACE.
[METHODS] Patients who had HCC with MVI were consecutively enrolled. Overall survival (OS) and recurrence-free survival (RFS) were compared between the PA-TACE and LR groups. Univariate and multivariate analyses were performed to identify independent prognostic factors for these patients. Subgroup survival analysis was conducted using the grading risk of MVI.
[RESULTS] The median OS and RFS of the PA-TACE group were significantly longer than the LR group. PA-TACE was associated with significantly better OS (P = 0.032) and RFS (P = 0.023) compared with LR alone. In subgroup analysis, there were no significant differences in prognosis between the PA-TACE and LR groups for HCC patients with low-risk MVI. For HCC patients with high-risk MVI, the PA-TACE group had significantly better prognosis than the LR group (for OS, P = 0.017; for RFS, P = 0.018).
[CONCLUSION] PA-TACE should be performed selectively in HCC patients with high-risk MVI after curative liver resection. Nonetheless, for HCC patients with low-risk MVI, PA-TACE is not recommended.
[METHODS] Patients who had HCC with MVI were consecutively enrolled. Overall survival (OS) and recurrence-free survival (RFS) were compared between the PA-TACE and LR groups. Univariate and multivariate analyses were performed to identify independent prognostic factors for these patients. Subgroup survival analysis was conducted using the grading risk of MVI.
[RESULTS] The median OS and RFS of the PA-TACE group were significantly longer than the LR group. PA-TACE was associated with significantly better OS (P = 0.032) and RFS (P = 0.023) compared with LR alone. In subgroup analysis, there were no significant differences in prognosis between the PA-TACE and LR groups for HCC patients with low-risk MVI. For HCC patients with high-risk MVI, the PA-TACE group had significantly better prognosis than the LR group (for OS, P = 0.017; for RFS, P = 0.018).
[CONCLUSION] PA-TACE should be performed selectively in HCC patients with high-risk MVI after curative liver resection. Nonetheless, for HCC patients with low-risk MVI, PA-TACE is not recommended.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Carcinoma
- Hepatocellular
- Liver Neoplasms
- Chemoembolization
- Therapeutic
- Female
- Male
- Middle Aged
- Neoplasm Invasiveness
- Hepatectomy
- Microvessels
- Aged
- Prognosis
- Neoplasm Grading
- Retrospective Studies
- Survival Rate
- Chemotherapy
- Adjuvant
- Adult
- Disease-Free Survival
- Hepatocellular carcinoma (HCC)
- Microvascular invasion (MVI)
- Postoperative adjuvant transarterial chemoembolization (PA-TACE)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.